(Incorporated in the Cayman Islands with limited liability) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Non-registered Shareholder(s) (Note 1) , Kontafarma China Holdings Limited (the "Company") — Notification of publication of the circular of discloseable and Connected transaction in relation to the construction contract for Beijing R&D complex (the "Current Corporate Communication" (Note 2) ) The English and Chinese versions of the Company's Current Corporate Communications are available on the Compan ...

(Incorporated in the Cayman Islands with limited liability) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Registered Shareholders, Kontafarma China Holdings Limited (the "Company") — Notice of publication of the circular of discloseable and Connected transaction in relation to the construction contract for Beijing R&D complex (the "Current Corporate Communication") If you for any reason have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 股東特別大會通告 茲通告華控康泰集團有限公司（「本公司」）謹訂於二零二五年十月二十日（星期一）上 午十時正假座香港灣仔謝斐道238號香港諾富特世紀酒店B3層宴會廳3號舉行股東 特別大會（「股東特別大會」）或其任何續會，藉以考慮並酌情通過（無論有否修訂）下 列決議案為本公司之普通決議案。除另有界定者外，本通告所用詞彙與本公司刊發 日期為二零二五年九月二十六日之通函中所定義者具有相同涵義。 普通決議案 「動議 (a) 全面批准、確認及追認本公司之直接全資附屬公司同方藥業集團有限公司（「同 方藥業」）（作為委託人）及北京清控中創工程建設有限公司（「北京清控」）（作為 承包商）所訂立日期為二零二五年八月十八日之建築合約（「北京建築合約」）， 據此同方藥業同意委聘北京清控作為總承包商以進行位於中國北京市延慶區八 達嶺鎮西康路2 3號的研發綜合樓及配套大門的建築工程，合約價為人民幣 33,672,360.58元（可 ...

為本公司股本中每股面值0.002港元股份 （附註二） 股之登記持有人， 股東特別大會代表委任表格 茲委任股東特別大會主席或 （附註三） 出席華控康泰集團有限公司（「本公司」）於二零二五年十月二十日（星期一）上午十時正在香港灣仔謝斐道238號香港諾富特世紀 酒店B3層宴會廳3號舉行之股東特別大會（「股東特別大會」）之代表委任表格： 地址為 本人╱吾等 （附註一） 地址為 為本人╱吾等之代表並以本人╱吾等名義出席股東特別大會（及其任何續會），並代表本人╱吾等行事，藉以考慮並酌情通過召 開股東特別大會通告（「通告」）所載之決議案（不論有否修訂），並於該股東特別大會（及其任何續會）以本人╱吾等名義，就該等 決議案按下文所載指示代表本人╱吾等投票。如無任何指示，則本人╱吾等之代表可酌情自行投票。 除另有界定者外，本代表委任表格所用之詞彙與本公司日期為二零二五年九月二十六日之通函所界定者具有相同涵義。 | | 普通決議案 | （附註五） 贊成 | （附註五） 反對 | | --- | --- | --- | --- | | (a) | 全面批准、確認及追認本公司之直接全資附屬公司同方藥業（作為委託 | | | | | 人 ...

此 乃 要 件 請 即 處 理 閣下如對本通函任何內容或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他持牌證 券交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓所有名下之華控康泰集團有限公司股份，應立即將本通函送交買方或承讓 人，或經手出售或轉讓之銀行、股票經紀或其他持牌證券交易商或其他代理人，以便轉交買方或 承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 有關 北京研發綜合樓建築合約的 須予披露及關連交易 本封面頁所用詞彙與本通函所界定者具相同涵義。董事會函件載於本通函第4至10頁。 董事會函件載於本通函第4至10頁。獨立董事委員會致獨立股東之推薦意見函載於本通函第11至 12頁。載有獨立財務顧問旭倫企業融資有限公司就北京建築合約及其項下擬進行的交易致獨立 董事委員會及獨立股東之意見之函件載於本通函第13至22頁。 股東特別大會謹訂於二零二五年十月二十日（星期一）上午十時正假座香港灣仔謝斐道238號香港 諾富特 ...

延遲寄發 有關 須予披露及關連交易的通函 茲提述華控康泰集團有限公司（「本公司」）日期為二零二五年八月十八日的公告（「該 公告」），內容有關就北京研發綜合樓項目所訂立的北京建築合約。除另有界定者 外，本公告所用詞彙與該公告所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 如該公告所述，一份載有（其中包括）(i)有關北京建築合約及其項下擬進行之交易的 進一步資料；(ii)獨立董事委員會向獨立股東提供的推薦建議；(iii)獨立財務顧問函 件，當中載有其有關上述事項的意見；及(iv)召開股東特別大會的通告連同代表委 任表格的通函（「該通函」），預期將於二零二五年九月八日或之前寄發予股東。 由於需要額外時間確定將載入該通函的若干資料，本公司正向聯交所申請豁免嚴格 遵守上市規則第14.41(a)條的規定，目前預期該通函的寄發日期將推遲至二零二五 年九月三十日或之前的日期。 承董事會命 華控康泰集團有限公司 主席 王飛飛 香港，二零二五年九 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 華控康泰集團有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01312 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | ...

Core Viewpoint - The company, Huakong Kante (01312.HK), reported a significant increase in net loss for the six months ending June 30, 2025, primarily due to challenges in its fitness franchise business and economic uncertainties [1] Financial Performance - The group's revenue and gross profit for the period were approximately HKD 452.7 million and HKD 254.6 million, representing a decline of about 1.3% and 8.1% respectively compared to the same period in 2024 [1] - The net loss for the group was approximately HKD 321.4 million, a substantial increase from a net loss of approximately HKD 4.5 million in 2024 [1] - Basic loss per share was approximately HKD 5.06, compared to earnings of approximately HKD 0.09 per share in 2024 [1] Business Challenges - The increase in net loss was attributed to a series of changes in the performance of the fitness franchise business, which faced slow recovery due to economic uncertainties and intensified competition [1] - The company's joint venture operating in Taiwan encountered operational difficulties and financial constraints, contributing to the financial losses [1] Impairment Losses - The group recorded significant impairment losses, including: - Expected credit loss model impairment of financial assets amounting to approximately HKD 159.0 million, compared to HKD 25.5 million in 2024 [1] - Impairment loss on intangible assets of approximately HKD 123.9 million, compared to HKD 13.6 million in 2024 [1] - Goodwill impairment loss in the fitness business segment of approximately HKD 88.4 million, whereas there was no such loss recorded in 2024 [1]

Group 1 - The company, Huakong Kante (01312), reported a revenue of HKD 453 million for the six months ending June 30, 2025, representing a year-on-year decrease of 1.3% [1] - The company recorded a loss attributable to shareholders of HKD 282 million, compared to a profit of HKD 4.745 million in the same period last year [1] - Basic loss per share was HKD 0.0506 [1] Group 2 - The significant increase in net loss was primarily due to changes in the company's fitness business franchise operations, which faced a slow recovery due to an uncertain economic outlook and intensified competition [1] - The company's joint venture in Taiwan encountered operational difficulties and financial constraints, leading to an expected credit loss model resulting in financial asset impairment losses of approximately HKD 159 million (compared to HKD 25.5 million in 2024) [1] - Impairment losses on intangible assets amounted to approximately HKD 124 million (compared to HKD 13.6 million in 2024), and goodwill impairment losses in the fitness business segment were approximately HKD 88.4 million (no losses reported in 2024) [1]

Core Viewpoint - Huakong Kantech (01312) reported a significant increase in net loss for the six months ending June 30, 2025, primarily due to challenges in its fitness franchise business and operational difficulties in its joint venture in Taiwan [1] Financial Performance - The company achieved revenue of HKD 453 million, a year-on-year decrease of 1.3% [1] - Shareholders' loss amounted to HKD 282 million, compared to a profit of HKD 4.745 million in the same period last year [1] - Basic loss per share was HKD 0.0506 [1] Business Challenges - The increase in net loss was attributed to a series of changes in the fitness franchise business, influenced by an uncertain economic outlook and intensified competition, leading to slower-than-expected business recovery [1] - The joint venture operating in Taiwan faced operational difficulties and financial constraints, contributing to significant impairment losses [1] Impairment Losses - The company recorded expected credit loss impairment of approximately HKD 159 million (2024: approximately HKD 25.5 million) [1] - Impairment loss on intangible assets was approximately HKD 124 million (2024: approximately HKD 13.6 million) [1] - Goodwill impairment loss in the fitness business segment was approximately HKD 88.4 million (2024: none) [1]